4
4Basebio PLC
LSE:4BB
4Basebio PLC
LSE:4BB
Price:
525
GBX
-2.78%
Market Closed
Market Cap:
£81.6m
Relative Value
The Relative Value of one 4BB stock under the Base Case scenario is hidden GBX. Compared to the current market price of 525 GBX, 4Basebio PLC is hidden .
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
4BB Relative Value
HIDDEN
Multiples Across Competitors
4BB Competitors Multiples
4Basebio PLC Competitors
4Basebio PLC Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| UK |
4
|
4Basebio PLC
LSE:4BB
|
81.4m GBP | 45.7 | -5.6 | -5.2 | -4.8 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
401.3B USD | 6.6 | 95.9 | 15.7 | 21.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
202.4B USD | 5.5 | 26.2 | 15 | 15 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
184.4B USD | 6.3 | 21.7 | 13.5 | 16.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
126.8B USD | 10.6 | 32.1 | 24.3 | 25.3 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.6B USD | 5.7 | 18.1 | 13.6 | 15.5 | |
| AU |
|
CSL Ltd
ASX:CSL
|
68.6B AUD | 3.2 | 34.9 | 11.5 | 14.5 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
39B EUR | 11.1 | 35.7 | 38.8 | 39.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
